Editas Medicine, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EDIT research report →
Companywww.editasmedicine.com
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.
- CEO
- Gilmore O'Neill
- IPO
- 2016
- Employees
- 246
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $250.15M
- P/E
- -2.30
- P/S
- 6.47
- P/B
- 56.73
- EV/EBITDA
- -1.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.75%
- Op Margin
- -297.50%
- Net Margin
- -281.59%
- ROE
- -677.39%
- ROIC
- -93.01%
Growth & Income
- Revenue
- $40.52M · 25.39%
- Net Income
- $-160,060,000 · 32.49%
- EPS
- $-1.80 · 37.50%
- Op Income
- $-99,336,000
- FCF YoY
- 24.31%
Performance & Tape
- 52W High
- $4.54
- 52W Low
- $1.47
- 50D MA
- $2.81
- 200D MA
- $2.65
- Beta
- 2.14
- Avg Volume
- 1.60M
Get TickerSpark's AI analysis on EDIT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 26 | O'Neill Gilmore Neil | other | 1,015,200 |
| Mar 12, 26 | Parison Amy | other | 292,856 |
| Mar 12, 26 | Burkly Linda | other | 292,856 |
| Mar 3, 26 | O'Neill Gilmore Neil | sell | 5,394 |
| Mar 3, 26 | Parison Amy | sell | 474 |
| Mar 3, 26 | Burkly Linda | sell | 749 |
| Dec 3, 25 | Burkly Linda | sell | 713 |
| Dec 3, 25 | O'Neill Gilmore Neil | sell | 5,603 |
| Dec 3, 25 | Parison Amy | sell | 461 |
| Sep 3, 25 | Burkly Linda | sell | 710 |
Our EDIT Coverage
We haven't published any research on EDIT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EDIT Report →